Dr. Kilian Kelly, Ph.D. is Chief Executive Officer and Managing Director of Cynata Therapeutics ( https://cynata.com/ ), a stem cell and regenerative medicine company that is known for its proprietary Cymerus platform, for the scalable and consistent production of mesenchymal stem cell (MSC)-based therapies.
Unlike traditional MSC therapies that rely on multiple donors, the Cymerus manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities from a single donor – making the opportunities endless and attractive from a manufacturing standpoint. The company has completed Phase I studies for Graft vs Host disease & Diabetic Foot Ulcers and have a number of Phase II, and even have a Phase III clinical trial, in progress.
Dr. Kelly has over 20 years’ experience in biopharmaceutical research and development, including almost 15 years focused on the development of mesenchymal stem cell (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer from May 2019, and since July 2023 has been CEO & MD. At Cynata, he has overseen all stages of the development of the Cymerus induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.
Dr. Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca.
Dr. Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a Ph.D. in Pharmaceutical Sciences from Strathclyde University, Glasgow, and he is a Graduate of the Australian Institute of Company Directors (AICD), Melbourne. He is a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Royal Pharmaceutical Society and the AICD.
Dr. Kelly also serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Working Group for the Development of PSC-Derived Therapies and the Industry Interface Committee of the Center for Commercialization of Regenerative Medicine (CCRM) Australia.
#KilianKelly #CynataTherapeutics #InducedPluripotentStemCells #MesenchymalStemCells #Immunomodulation #Immunoregulation #Mesenchymoangioblasts #GraftVersusHostDisease #GVHD #MSC #iPSC #IschaemicHeartDisease #Osteoarthritis #AcuteRespiratoryDistressSyndrome #ARDS #Inflammation #Secretome #Paracrine #RegenerativeMedicine #DiabeticWounds #KidneyTransplantation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Boysober
Have you ever wondered what life might be like if you stopped worrying about being wanted, and focused on understanding what you actually want? That was the question Hope Woodard asked herself after a string of situationships inspired her to take a break from sex and dating. She went "boysober," a personal concept that sparked a global movement among women looking to prioritize themselves over men. Now, Hope is looking to expand the ways we explore our relationship to relationships. Taking a bold, unfiltered look into modern love, romance, and self-discovery, Boysober will dive into messy stories about dating, sex, love, friendship, and breaking generational patterns—all with humor, vulnerability, and a fresh perspective.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com